The American College of Cardiology (ACC) and the American Heart Association (AHA) have released a Focused Update to the Practice Guidelines based on new clinical trial data on the risks and benefits of using beta blockers to reduce cardiac events during non-cardiac surgeries. It provides specific recommendations about which patients will likely benefit from beta blockers and in which patients there is not enough evidence to recommend their use.
“Any surgery, particularly a high-risk procedure, is a stress on the heart, especially for those with underlying circulation problems or other cardiovascular risk factors,” said Kirsten E. Fleischmann, MD, chair of the 2009 writing group that reviewed the latest evidence on the perioperative use of beta blockers. “In general, the higher the risk from a cardiovascular standpoint, the more likely a patient will benefit from beta blockers. However, newer data from the POISE [Perioperative Ischemic Evaluation] trial suggest that starting higher doses of beta blockers acutely on the day of surgery is associated with risk as well, so careful patient selection, dose adjustment and monitoring throughout the perioperative period is key.”
The recommendation to continue beta blockers perioperatively in those patients who are already receiving them remains current since the initial 2007 guidelines were published.
The workgroup advised beta blockers are reasonable to consider in:
- Patients at high risk for heart attacks or other cardiac complications because of abnormal stress test results or known coronary artery disease who undergo vascular surgery.
- High-risk patients undergoing intermediate risk surgery or in those with multiple risk factors for complications (e.g., diabetes, a history of heart failure, significant kidney disease) who undergo vascular surgery.
However, the authors cautioned that when beta blockers are started in patients not yet taking them, the medication should be initiated well before the procedure and titrated up as blood pressure and heart rate allow.
“We recommend beta blockers be started well in advance of surgery and not at higher doses right off the bat,” Fleischmann said. “These updated guidelines are intended to provide guidance for the appropriate use of beta blockers to help reduce the risk of cardiac complications. Physicians must be vigilant in assessing patients’ cardiac risk and weighing this against potential side effects of the therapy.”
According to the authors, the usefulness of beta blockers remains uncertain in lower-risk patients or in those undergoing lower-risk surgeries (e.g., percutaneous or endovascular procedures) and requires careful consideration of the risks and benefits.
The guidelines do not advocate for routine administration of beta blockers, particularly in higher fixed-dose regimens, begun on the day of surgery based on data from the POISE study. While there was a reduction in perioperative MI and primary cardiac events among study participants, the use of beta blockers was also associated with higher rates of stroke and overall mortality. Beta blockers should not be used when contraindications exist.
The ACC/AHA update was developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine, and Society for Vascular Surgery.
The full text of the update will be published in the Nov. 24 issue of the Journal of the American College of Cardiology and Circulation.